Rifaximine in the Treatment of Hepatic Encephalopathy
Lata J.1 , Hůlek P.2 , Fejfar T.2 , Špičák J.3 , Drastich P.3 , Mareček Z.4 , Brůha R.4 ,Husová L.1 , Šenkyřík M.1
1 Interní astroenterolo ická klinika FN Brno, pracovište Bohunice, přednosta prof. MUDr. P.Dítě, DrSc 2 Katedra interních oboru Lékarské fakulty UK Praha a Fakultní nemocnice Hradec Králové, přednosta prof. MUDr. J. Malý, DrSc. 3 Klinika hepato astroenterologie IKEM, Praha, přednosta doc. MUDr. J. Špicák, CSc. 4 IV. Interní klinika 1. Lékařské fakulty UK a VFN Praha, přednosta doc. MUDr. A. Žák, CSc. |
|
Summary:
Hepatic encephalopathy is a frequent and serious complication of liver cirrhosis . Usually it is
treated by non-ab orbable disaccharide or antibiotic and it treatment is often difficult and
asociated with undesirable effect . The objective of our investigation was to evaluate the safety
and effectiveness of a new antibiotic used in this indication - rifaximine. With rifaximine, 400 mg
three time per day, a total of 25 patients were treated for a 10-day period. Significant improvement
of the manifestation of encephalopathy occurred (evaluated by the grade of encephalopathy,
test of combining numeral , the degree of flapping tremor and the arterial ammonia level).
None of the patient developed unde irable effect . Rifaximine eem an effective, safe drug for
hepatic encephalopathy.
Key words:
Liver cirrhosis - Liver encephalopathy - Non-absorbable antibiotic - Rifaximine
|
